Open an account

Kymera Therapeutics

KYMR · NASDAQ

$113.46+$5.39 (+4.99%)TodayMarket closed ·
Prev close $108.07

About KYMR

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. The company is headquartered in Watertown, Massachusetts and currently employs 253 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The firm's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. The company is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. The company is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.

Employees
253
Headquarters
Watertown, Massachusetts
Listed
Aug 21, 2020
Sector
Health Care
Industry
Biotechnology
Website
kymeratx.com

KYMR key statistics

Market cap
8.99B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
843.25K
Volume
705.09K
Open price
$108.75
High today
$115.28
Low today
$108.49
52 Week high
$130.05
52 Week low
$55.26

Kymera Therapeutics (KYMR) at a glance

Kymera Therapeutics (KYMR) last traded at $113.46, with a market cap of 8.99B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $108.49 and $115.28. The current price is 4.6% above the day's low and 1.6% below its high.

Volume so far is 705.09K shares, in line with the average of 843.25K shares a day.

Over the past year Kymera Therapeutics has ranged from $55.26 to $130.05, and now sits 78% of the way up that range.

Kymera Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.62 per share against an estimate of -$0.7273.

The average analyst price target is $141.34, 24.6% above the current price, from 26 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 26 analyst ratings say Buy
  • Buy92.3%
  • Hold7.7%
  • Sell0.0%
Price target · 24 analystsAvg $141.34
Low
$112.11
Now
$113.46
High
$189.00

KYMR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 13.1% on average.

  1. Q3 FY24: reported -$0.82 per share against an estimate of -$0.8555
  2. Q4 FY24: reported -$0.88 per share against an estimate of -$0.79
  3. Q1 FY25: reported -$0.82 per share against an estimate of -$0.9346
  4. Q2 FY25: reported -$0.95 per share against an estimate of -$0.8262
  5. Q3 FY25: reported -$0.94 per share against an estimate of -$0.82
  6. Q4 FY25: reported -$0.97 per share against an estimate of -$0.8122
  7. Q1 FY26: reported -$0.71 per share against an estimate of -$0.8993
  8. Q2 FY26: reported -$0.62 per share against an estimate of -$0.7273

KYMR news

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

  • Press releaseGlobe Newswire

    Kymera Therapeutics to Participate in Upcoming September Investor Conferences

  • Press releaseGlobe Newswire

    Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

  • Press releaseGlobe Newswire

    Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

  • Press releaseGlobe Newswire

    Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Similar companies

Companies in the same industry as Kymera Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.